Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 9:37 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–136 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Namenda/Memantine Clear all
Terminated Phase 2 Interventional Results available

Memantine for Recurrent Glioblastoma

NCT01260467
View directory record Official record
Conditions
Glioblastoma
Interventions
memantine
Drug
Lead sponsor
University of Rochester
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2015 · Synced Oct 7, 2026, 9:37 PM EDT
Recruiting Phase 2 Interventional

The Study of Atezolizumab, Bevacizumab and Memantine in Patients With Hepatocellular Carcinoma (HCC)

NCT06789757
View directory record Official record
Conditions
Hepatocellular Carcinoma
Interventions
Memantine Hydrochloride, Bevacizumab, Atezolizumab
Drug
Lead sponsor
Inova Health Care Services
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
2
States / cities
Fairfax, Virginia • Falls Church, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 7, 2025 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Therapy in Amyotrophic Lateral Sclerosis (TAME)

NCT02118727
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia
Interventions
Memantine, Placebo (for Memantine)
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
13
States / cities
Phoenix, Arizona • Irvine, California • Jacksonville, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2022 · Synced Oct 7, 2026, 9:37 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Treatment of Orthostatic Intolerance

NCT00262470
View directory record Official record
Conditions
Tachycardia, Chronic Orthostatic Intolerance
Interventions
Acetazolamide, Atomoxetine, NO Drug, Clonidine, Entacapone, Entacapone & Propranolol, Atomoxetine & Propranolol, Indomethacin, Mecamylamine, Isosorbide Dinitrate, Melatonin, Midodrine, Modafinil, Octreotide, Placebo, Propranolol, Modafinil & Propranolol, Sertraline, IV Saline, Drinking Water, Breathing Device, memantine, Abdominal binder
Drug · Other · Dietary Supplement + 3 more
Lead sponsor
Satish R. Raj
Other
Eligibility
18 Years to 70 Years
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1997 – 2029
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Oct 7, 2026, 9:37 PM EDT
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

The Use of Memantine for Prevention of Alzheimer's Disease

NCT05063851
View directory record Official record
Conditions
Alzheimer Disease
Interventions
Memantine Hydrochloride Tablets, Placebo
Drug
Lead sponsor
University of Virginia
Other
Eligibility
50 Years to 65 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Family History Study of Alcohol Consumption Using Memantine

NCT00630955
View directory record Official record
Conditions
Alcohol Drinking
Interventions
Memantine, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 50 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Delaying the Progression of Driving Impairment in Individuals With Mild Alzheimer's Disease

NCT00476008
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Memantine, Placebo
Drug
Lead sponsor
Florida Atlantic University
Other
Eligibility
60 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boca Raton, Florida
Source: ClinicalTrials.gov public record
Updated Aug 11, 2014 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Results available

Memantine (10mg BID) for the Frontal and Temporal Subtypes of Frontotemporal Dementia

NCT00545974
View directory record Official record
Conditions
Frontal Lobe Dementia, Frontotemporal Lobe Dementia, Semantic Dementia
Interventions
memantine, Placebo pill
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
40 Years to 80 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
9
States / cities
Los Angeles, California • San Francisco, California • Jacksonville, Florida + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2020 · Synced Oct 7, 2026, 9:37 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Down Syndrome Memantine Follow-up Study

NCT02304302
View directory record Official record
Conditions
Down Syndrome, Intellectual Disability
Interventions
Memantine, Placebo
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
15 Years to 32 Years
Enrollment
160 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 27, 2023 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Early Phase 1 Interventional

Memantine for the Reduction of Cognitive Impairment After Radiation Therapy in Pediatric Patients With Central Nervous System Tumors

NCT04217694
View directory record Official record
Conditions
Malignant Central Nervous System Neoplasm, Primary Central Nervous System Neoplasm
Interventions
Cogstate Assessment Battery, Memantine, Memantine Hydrochloride
Behavioral · Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
4 Years to 18 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 7, 2026, 9:37 PM EDT
Recruiting Phase 2 Interventional

Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

NCT07248228
View directory record Official record
Conditions
Brain Metastases
Interventions
MA-WBRT (Memory Avoidance Whole Brain Radiation Therapy (MA-WBRT)), HA-WBRT (Hippocampal Avoidance Whole Brain Radiation Therapy (HA-WBRT)), Memantine
Radiation · Drug
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 2 Interventional Results available

Memantine Treatment of Compulsive Buying

NCT00830375
View directory record Official record
Conditions
Compulsive Buying
Interventions
Memantine
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
2
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Oct 7, 2026, 9:37 PM EDT
Completed No phase listed Observational

Memantine XR and Pregabalin for Chemotherapy-Induced Peripheral Neuropathy

NCT03709888
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy
Interventions
Memantine XR-pregabalin combination therapy
Drug
Lead sponsor
Saint John's Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Apr 6, 2022 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 2 Interventional

A Study of RO4602522 in Participants With Moderate Severity Alzheimer Disease on Background Alzheimer Disease Therapy

NCT01677754
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
RO4602522, Placebo, Donepezil, Memantine, Rivastigmine, Galantamine
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
50 Years to 90 Years
Enrollment
542 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
42
States / cities
Anaheim, California • Fullerton, California • Lomita, California + 36 more
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 7, 2026, 9:37 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Memantine Effects on Sensorimotor Gating and Neurocognition in Schizophrenia

NCT03860597
View directory record Official record
Conditions
Schizophrenia, Schizo Affective Disorder, Schizoaffective Disorder, Healthy
Interventions
Memantine, Placebos
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 50 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 7, 2026, 9:37 PM EDT